Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for graft-versus-host disease in allogeneic antitumor cell therapy

Bibliography

• RASO V, GRIFFIN T: Hybrid antibody with dual specificity for the delivery of ricin to immunoglobin bearing target cells. Cancer Res. (1981) 41:2073-2078.
   PubMed Web of Science ®Google Scholar
• TITUS JA, PEREZ P, KAUBISCH A, GARRIDO MA, SEGAL DM: Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. (1987) 139:3153-3158.
   PubMed Web of Science ®Google Scholar
• PEREZ P, TITUS JA, LOTZE MT et al.: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J. Immunol. (1986) 137:2069-2072.
   PubMed Web of Science ®Google Scholar
• SEGAL DM, GARRIDO MA, PEREZ P et al.: Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol. Immunol. (1988) 25:1099-1103.
   PubMed Web of Science ®Google Scholar
• ZEIDLER R, MYSLIWIETZ J, CSANADY M et al.: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer (2000) 83:261-266.
   PubMed Web of Science ®Google Scholar
• RENNER C, HELD G, OHNESORGE S et al.: Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol. Immunother. (1997) 44:70-76.
   PubMed Web of Science ®Google Scholar
• RENNER C, PFREUNDSCHUH M: Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. J. Hematother. (1995) 4:447-451.
   PubMedGoogle Scholar
• RENNER C, STEHLE I, LEE FT et al.: Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system. Cancer Immunol. Immunother. (2001) 50:102-108.
   PubMed Web of Science ®Google Scholar
• ESHHAR Z, GROSS G, WAKS T et al.: T bodies: chimeric T cell receptors with antibody-type specificity. Meth. Enzymol. Methods (1995) 8:133-142.
   Google Scholar
• OSADA T, CLAY TM, WOO CY, MORSE MA, LYERLY HK: Dendritic cell-based immunotherapy. Int. Rev. Immunol. (2006) 25:377-413.
   PubMed Web of Science ®Google Scholar
• KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76:2462-2465.
   PubMed Web of Science ®Google Scholar
• KOLB HJ, HOLLER E: Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol. (1997) 9:139-145.
   PubMedGoogle Scholar
• CHILDS R, CHERNOFF A, CONTENTIN N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. (2000) 343:750-758.
   PubMed Web of Science ®Google Scholar
• BISHOP MR, FOWLER DH, MARCHIGIANI D et al.: Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. (2004) 22:3886-3892.
   PubMed Web of Science ®Google Scholar
• DE GAST GC, VAN HOUTEN AA, HAAGEN IA et al.: Clinical experience with CD3 x CD19 bispecific antibodies in patients with B-cell malignancies. J. Hematother. (1995) 4:433-437.
   PubMedGoogle Scholar
• KROESEN BJ, NIEKEN J, SLEIJFER DT et al.: Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol. Immunother. (1997) 45:203-206.
   PubMed Web of Science ®Google Scholar
• WEINER LM, CLARK JI, DAVEY M et al.: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res. (1995) 55:4586-4593.
   PubMed Web of Science ®Google Scholar
• VALONE FH, KAUFMAN PA, GUYRE PM et al.: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. (1995) 13:2281-2292.
   PubMed Web of Science ®Google Scholar
• JAMES ND, ATHERTON PJ, JONES J, HOWIE AJ, TCHEKMEDYIAN S, CURNOW RT: A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br. J. Cancer (2001) 85:152-156.
   PubMed Web of Science ®Google Scholar
• POSEY JA, RASPET R, VERMA U et al.: A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J. Immunother. (1999) 22:371-379.
   PubMed Web of Science ®Google Scholar
• HARTMANN F, RENNER C, JUNG W et al.: Treatment of refractory Hodgkin's disease with an anti-CD16/Cd30 bispecific antibody. Blood (1997) 89:2042-2047.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, SCHNELL R, FUSS I et al.: Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood (2002) 100:3101-107.
   PubMed Web of Science ®Google Scholar
• NITTA T, SATO K, YAGITA H, OKUMURA K, ISHII S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet (1990) 335:368-371.
   PubMed Web of Science ®Google Scholar
• JUNG G, BRANDL M, EISNER W et al.: Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ T cell activation and therapeutic efficacy. Int. J. Cancer (2001) 91:225-230.
   PubMed Web of Science ®Google Scholar
• LAMERS CH, VAN DE GRIEND RJ, BRAAKMAN E, RONTELTAP CP, BÉNARD J, STOTER G: Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody- directed cellular immunotherapy. Int. J. Cancer (1992) 51:973-979.
   PubMed Web of Science ®Google Scholar
• CANEVARI S, STOTER G, ARIENTI F et al.: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. (1995) 87:1463-1469.
   PubMed Web of Science ®Google Scholar
• SEN M, WANKOWSKI DM, GARLIE NK et al.: Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu tumors. J. Hematother. Stem Cell Res. (2001) 10:247-260.
   PubMedGoogle Scholar
• GRABERT RC, SMITH J, TIGGS J, KOUTTAB N, LUM LG: Anti-CD3 activated T cells armed with OKT3 x herceptin bispecific antibody, survive and divide, and secrete cytokines and chemokines after multiple cycles of killing directed at Her2/neu+ tumor targets. Am. Assoc. Cancer Res. (2003) 44:656a.
   Google Scholar
• CLARK M, GILLILAND L, WALDMANN H: The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. Int. J. Cancer Suppl. (1988) 2:15-17.
   PubMedGoogle Scholar
• RUF P, LINDHOFER H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood (2001) 98:2526-2534.
   PubMed Web of Science ®Google Scholar
• DE GAST GC, HAAGEN I-A, VAN HOUTEN AA et al.: CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. (1995) 40:390-396.
   PubMedGoogle Scholar
• GROSSE-HOVEST L, HARTLAPP I, MARWAN W, BREM G, RAMMENSEE HG, JUNG G: A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol. (2003) 33:1334-1340.
   PubMed Web of Science ®Google Scholar
• SEGAL DM, SCONOCCHIA G, TITUS JA, JOST CR, KURUCZ I: Alternative triggering molecules and single chain bispecific antibodies. J. Hematother. (1995) 4:377-382.
   PubMedGoogle Scholar
• MORECKI S, LINDHOFER H, YACOVLEV E, GELFAND Y, SLAVIN S: Use of trifunctional bispecific antibodies to prevent graft-versus-host disease induced by allogeneic lymphocytes. Blood (2006) 107:1564-1569.
   PubMed Web of Science ®Google Scholar
• RIESENBERG R, BUCHNER A, POHLA H, LINDHOFER H: Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (α EpCAM x α CD3). J. Histochem. Cytochem. (2001) 49:911-17.
   PubMed Web of Science ®Google Scholar
• REN-HEIDENREICH L, DAVOL PA, KOUTTAB NM, ELFENBEIN GJ, LUM LG: Redirected T-cell cytotoxicity to EpCAM over-expressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer (2004) 100:1095-1103.
   PubMed Web of Science ®Google Scholar
• GALL JM, DAVOL PA, GRABERT RC, DEAVER M, LUM LG: T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B-cells and bypass compliment-mediated rituximab resistance in vitro. Ex. Hematol. (2005) 33:452-459.
   Google Scholar
• BOHLEN H, HOPFF T, MANZKE O et al.: Lysis of malignant B-cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood (1993) 82:1803-1812.
   PubMed Web of Science ®Google Scholar
• BOHLEN H, MANZKE O, PATEL B et al.: Cytolysis of leukemic B-cells by T cells activated via two bispecific antibodies. Cancer Res. (1993) 43:4310-4314.
   Google Scholar
• ANDERSON PM, CRIST W, HASZ D, CARROLL AJ, MYERS DE, UCKUN FM: G19.4(αCD3) x B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood (1992) 80:2826-2834.
   PubMed Web of Science ®Google Scholar
• BEJECK BE, WANG D, BERVEN E et al.: Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. (1995) 55:2346-2351.
   PubMed Web of Science ®Google Scholar
• KLEIN SC, BOER LH, DE WEGER RA, DE GAST GC, BAST EJ: Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19. Scand. J. Immunol. (1997) 46:452-458.
   PubMed Web of Science ®Google Scholar
• GRABERT RC, COUSENS LP, SMITH JA et al.: Human activated T cells armed with anti-CD3 x anti-Her2/neu bispecific antibodies divide, mediate specific cytotoxicity and secrete cytokines with repeated Her2/neu+ target stimulation in vitro and induce specific cytotoxicity in patient PBMC populations. Clin. Cancer Res. (2006) 12:569-576.
   PubMed Web of Science ®Google Scholar